Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387837 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
A Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Ashvattha Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 16
- Study locations
NCT05387837: Active Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by Ashvattha Therapeutics.
NCT05387837 is a Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by Ashvattha Therapeutics. The registered enrollment target is 50 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05387837, a Phase 2 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Ashvattha Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 16
- Study locations
Study Summary
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
Primary Outcome
Safety of single dose of D-4517.2 as measured by Treatment-Emergent Adverse Events (TEAEs)
Conditions Studied
Interventions
- DRUG D-4517.2
Study Locations (16)
Texas
- Texas Retina Associates - Arlington - Arlington
- Austin Retina Associates - Austin
- Medical Center Ophthalmology Associates - Northwest - San Antonio
- Retinal Consultants of San Antonio - San Antonio
- Strategic Clinical Research Group - Willow Park
Missouri
- Springield Clinic - Springfield
- The Retina Institute - Clayton Office - St Louis
California
- Macro Trials - Los Angeles
Illinois
- University Retina - Lemont - Lemont
Indiana
- Midwest Eye Institute - North - Indianapolis
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Massachusetts
- Ophthalmic Consultants of Boston - Boston
New Jersey
- Envision Ocular, LLC - Bloomfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
What the registry record for NCT05387837 still lists
NCT05387837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which D-4517.2 is the first listed.
NCT05387837 lists 16 locations in 11 states (Texas, Missouri, California).
Frequently Asked Questions
What is clinical trial NCT05387837 about?
NCT05387837 is a clinical study titled "Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME". A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME)
What is the current status of trial NCT05387837?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-08-31. Estimated completion is 2025-09-30.
What conditions does trial NCT05387837 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05387837?
The interventions under investigation include: D-4517.2 (DRUG).
Who is sponsoring clinical trial NCT05387837?
This trial is sponsored by Ashvattha Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05387837 being conducted?
This trial has 16 study locations across California, Illinois, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05387837's enrollment target sits among peer trials
50 36th of 63 higher than 27 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI